Imbio PHA (4.0.0) vs Tempus ECG-AF
AI Verdict
Choose Imbio PHA (4.0.0) if…
Choose Imbio PHA if your clinical workflow involves CT pulmonary angiogram (CTPA) scans and you require rapid, automated measurement of cardiac structures to assess potential right ventricular dilation. This tool is ideal for aiding in the diagnosis and risk stratification of pulmonary embolism and hypertension, providing quantitative insights directly from imaging data.
View Imbio PHA (4.0.0) →Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if your objective is to proactively identify patients aged 65 or older who are at an increased risk of developing new-onset atrial fibrillation/flutter within the next 12 months, utilizing standard 12-lead ECG recordings. This solution is best suited for integrating into routine cardiology or primary care screenings to support earlier identification and follow-up for at-risk elderly patients without pre-existing AF.
View Tempus ECG-AF →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Imbio PHA (4.0.0) | Tempus ECG-AF |
|---|---|---|
| Pricing | Unknown | Contact vendor |
| Deployment | Cloud (AWS) or On-premise (VMware) or via partners (Nuance, Aidoc, Siemens Syngo.via, TeraRecon, FerrumHealth, Flywheel). | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Yes AI-estimated | Yes AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Imbio PHA (4.0.0)Imbio PHA integrates with native DICOM tools and workflows, generates annotated DICOM images, and provides summary reports in PDF format, facilitating direct clinician review within existing systems. In contrast, Tempus ECG-AF explicitly states it 'does not have a dedicated user interface (UI)', suggesting a more backend, integrated solution that may offer less direct clinician interaction.
Clinical Value
TieBoth tools offer significant and distinct clinical value. Imbio PHA aids in the diagnosis and risk stratification of pulmonary embolism and hypertension by assessing right ventricular dilation from CTPA scans. Tempus ECG-AF identifies patients at increased risk of developing atrial fibrillation/flutter within 12 months from ECG recordings, supporting earlier identification and follow-up. Both are FDA-cleared and address critical cardiovascular conditions.
Pricing & Value
Tempus ECG-AFTempus ECG-AF provides clear transparency regarding its financial value proposition by stating that CMS reimbursement is available with specific CPT codes and a Medicare rate of $128.90, effective January 1, 2025. Imbio PHA, on the other hand, only states 'contact for pricing,' offering no public information on cost or reimbursement pathways.
Enterprise Readiness
Imbio PHA (4.0.0)Imbio PHA demonstrates greater enterprise readiness through its flexible deployment options, including Cloud, Enterprise (on-premise), or via partners. While Tempus ECG-AF integrates into healthcare facility systems, Imbio's explicit mention of multiple deployment models caters to a wider range of organizational IT infrastructures and preferences.
Innovation
Tempus ECG-AFTempus ECG-AF showcases a higher degree of innovation by applying AI to predict the *future risk* of atrial fibrillation within 12 months, a predictive analytics capability. This is further supported by its training on a large dataset of over 1.5 million ECGs from 500,000 patients. Imbio PHA, while valuable, focuses on automated measurement of existing cardiac structures from CT scans.
Support & Docs
Imbio PHA (4.0.0)Imbio PHA explicitly provides an online user manual available at its support documentation page and a direct support email address. Tempus ECG-AF offers contact information for a dedicated Cardiology Support team via email and phone. However, the explicit availability of a user manual for Imbio PHA provides a clear advantage in terms of readily accessible self-service documentation.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Imbio PHA (4.0.0) | Tempus ECG-AF |
|---|---|---|
| Primary Function/Purpose | Automatically measures cardiac structures from CT pulmonary angiogram (CTPA) scans to assess potential right ventricular dilation and aid in the diagnosis and risk stratification of pulmonary embolism and hypertension. | Analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up. |
| Input Data Type | CT pulmonary angiogram (CTPA) scans | 12-lead ECG recordings |
| Output/Measurements | Automated measurement of right and left ventricle diameters, main pulmonary artery and aorta diameters; calculates RV/LV and PA/Ao ratios; generates annotated DICOM images and summary reports in PDF format. | Detects signs associated with new onset Atrial Fibrillation (AF) within 12 months. |
| Target Patient Population/Use Case | Aids in diagnosis and risk stratification of pulmonary embolism and hypertension. | Patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery, at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months. |
| Specialties Supported | Cardiology, Pulmonology, Radiology | Cardiology, Geriatrics, Internal Medicine |
| Company Tagline | Transforming Imaging with AI to turn medical images into life-changing insights. | Advancing precision medicine through the practical application of artificial intelligence in healthcare. |
Videos
Demos, reviews, and walkthroughs featuring Imbio PHA (4.0.0) and Tempus ECG-AF.